Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans | Zendy

Edward P. Weiss | Zendy; Dennis T. Villareal | Zendy; Luigi Fontana | Zendy; DongHo Han | Zendy; John O. Holloszy | Zendy

Open Access

Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans

Author(s) -

Edward P. Weiss,

Dennis T. Villareal,

Luigi Fontana,

DongHo Han,

John O. Holloszy

Publication year - 2011

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.100327

Subject(s) - dehydroepiandrosterone , insulin resistance , medicine , placebo , endocrinology , insulin , randomized controlled trial , hormone , androgen , alternative medicine , pathology

Plasma dehydroepiandrosterone (DHEA) decreases ~80% between ages 25 and 75 yr. In a preliminary study, we found that 6 mo of DHEA replacement improved insulin action in elderly individuals. The purpose of the present larger, randomized double-blind study was to determine whether a longer period of DHEA replacement improves glucose tolerance. Fifty-seven men and 68 women aged 65 to 75 yr were randomly assigned to 50 mg DHEA or placebo once daily. Year one was a randomized, double blind trial. Year 2 was an open label continuation. DHEA replacement improved glucose tolerance in participants who had abnormal GT initially, reduced plasma triglycerides, and the inflammatory cytokines IL6 and TNFα.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research